Formação in vitro de túbulos capilares a partir de células de sangue de cordão umbilical humano com perspectivas para aplicação terapêutica

Abstract

ResumoObjetivo: As células progenitoras endoteliais (CPE), caracterizadas pelo marcador CD133+, contribuem para a neovascularização, e o aumento no número dessas células pode ser uma ferramenta terapêutica promissora. O sangue de cordão umbilical humano contém um número significante de CPE, sugerindo a possibilidade do uso destas células para a revascularização de tecidos isquêmicos. O objetivo desse trabalho foi analisar a funcionalidade das células CD133+ diferenciadas in vitro.Métodos: As células diferenciadas foram caracterizadas 468SENEGAGLIA, AC ET AL -In vitro formation of capillary tubules from human umbilical cord blood cells with perspectives for therapeutic application Bras Cir Cardiovasc 2008; 23(4): 467-473 Rev

Human Cord Blood-Derived AC133+ Progenitor Cells Preserve Endothelial Progenitor Characteristics after Long Term In Vitro Expansion

“…Cells maintained under the growth (non-differentiating) conditions also expressed CD105, CD29 and CD184; however, these molecules were strongly upregulated and expressed on 100% of cells that were cultured under the differentiating conditions. The CD105 increase under the differentiating conditions also correlated to the data gained from the study by Senegaglia et al [38]. Collectively, these data are in agreement with the expected changes in cell shape, motility and ability to migrate that are associated with EC differentiation and at the same time are the properties necessary to carry out angiogenic effects of mature endothelial cells.…”

“…The observed down-regulation of CD133 and CD34 molecules with the increased time in culture indicated the presence of more mature endothelial progenitors. Although this phenomenon has been previously reported, the time points when significant decrease in the percentage of cells expressing CD133 and CD34 was detected ranged from day 7 to day 30 after isolation of AC133+ cells [38], [41], [42], [43]. The discrepancy in the observed dynamic of CD133 and CD34 expression, as well as in CD31, CD105, CD184, CD29 and CD117 expression may reflect the differences in culture conditions with regard to cytokine compositions and cell growth surface employed by distinct groups.…”

“…Previous work have shown that the numbers of EPCs generated from cord blood are higher (up to 0.64%) than the numbers generated from human peripheral blood [13], [38]. In addition, CB AC133+ cells represent a multipotent adult stem/progenitor cell population that can self-renew and differentiate to a variety of specialized cells [38], [39], [40]. Taken together, currently available data indicate that CB AC133+ cells may be one of the best candidates for developing therapies for vascular ischemic diseases.…”

“…In recent years, human umbilical cord blood became an interesting source of various types of stem/progenitor cells [33], [34], [35], including hematopoietic [36], [37] and AC133+ stem/progenitor cells. Previous work have shown that the numbers of EPCs generated from cord blood are higher (up to 0.64%) than the numbers generated from human peripheral blood [13], [38]. In addition, CB AC133+ cells represent a multipotent adult stem/progenitor cell population that can self-renew and differentiate to a variety of specialized cells [38], [39], [40].…”

Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy

“…CD133 has been shown to play a role in postnatal physiologic and pathologic angiogenesis [25-27]. Several studies have demonstrated that tumor growth and -aggressiveness is directly correlated with the degree of neovascularization [28].…”